The global market for Companion Diagnostics was valued at US$15.1 Billion in 2024 and is projected to reach US$15.4 Billion by 2030, growing at a CAGR of 0.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Companion Diagnostics market.
The technological advancements in molecular diagnostics and genomics are significantly driving the evolution of companion diagnostics. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) are among the key technologies that have enhanced the precision and speed of companion diagnostics. These technologies enable comprehensive genomic profiling and accurate detection of genetic mutations and alterations associated with various diseases, particularly cancer. Additionally, the integration of artificial intelligence (AI) and machine learning in data analysis has further refined the accuracy of these diagnostics, allowing for more precise and reliable results. The development of multiplex assays, which can detect multiple biomarkers simultaneously, has also expanded the scope and efficiency of companion diagnostics. This technological progress is not only improving diagnostic capabilities but also fostering collaborations between pharmaceutical companies and diagnostic manufacturers to co-develop drugs and companion tests, thereby accelerating the delivery of personalized therapies to patients.
The growth in the companion diagnostics market is driven by several factors. The increasing prevalence of cancer and other chronic diseases necessitates the development of targeted therapies, which in turn boosts the demand for companion diagnostics. Regulatory agencies, such as the FDA, are emphasizing the importance of companion diagnostics in the drug approval process, encouraging pharmaceutical companies to incorporate these tests into their clinical development strategies. The rise of precision medicine and the growing adoption of personalized treatment approaches are also propelling market growth. Furthermore, advancements in molecular diagnostics technologies, such as NGS and digital PCR, are enhancing the accuracy and efficiency of companion diagnostics, making them more accessible and reliable. The expansion of biomarker discovery and the increasing use of biomarkers in drug development are generating new opportunities for the market. Additionally, the collaboration between diagnostic companies and pharmaceutical firms is fostering innovation and accelerating the development of new companion diagnostics. These factors collectively contribute to the robust growth and widespread adoption of companion diagnostics, transforming the landscape of personalized medicine and improving patient care.
Segments: Product & Service (Assay kits & Reagents, Software & Services); Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Other Technologies); Indication (Oncology, Neurology, Other Indications); End-Use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Companion Diagnostics - Key Trends and Drivers
Companion diagnostics are an integral component of precision medicine, designed to identify the suitability of specific treatments for individual patients based on their unique genetic makeup or other biomarkers. These diagnostic tests are critical in the field of oncology, where they help determine the most effective therapies for cancer patients, ensuring treatments are tailored to the molecular profile of a patient's tumor. By enabling personalized treatment plans, companion diagnostics improve the efficacy and safety of therapies, reduce adverse effects, and ultimately enhance patient outcomes. They work by identifying patients who are most likely to benefit from a particular therapeutic product, ensuring that the right drug is administered to the right patient at the right time. This approach is transforming the landscape of medical treatment, moving away from the one-size-fits-all model to more targeted and individualized care.The technological advancements in molecular diagnostics and genomics are significantly driving the evolution of companion diagnostics. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) are among the key technologies that have enhanced the precision and speed of companion diagnostics. These technologies enable comprehensive genomic profiling and accurate detection of genetic mutations and alterations associated with various diseases, particularly cancer. Additionally, the integration of artificial intelligence (AI) and machine learning in data analysis has further refined the accuracy of these diagnostics, allowing for more precise and reliable results. The development of multiplex assays, which can detect multiple biomarkers simultaneously, has also expanded the scope and efficiency of companion diagnostics. This technological progress is not only improving diagnostic capabilities but also fostering collaborations between pharmaceutical companies and diagnostic manufacturers to co-develop drugs and companion tests, thereby accelerating the delivery of personalized therapies to patients.
The growth in the companion diagnostics market is driven by several factors. The increasing prevalence of cancer and other chronic diseases necessitates the development of targeted therapies, which in turn boosts the demand for companion diagnostics. Regulatory agencies, such as the FDA, are emphasizing the importance of companion diagnostics in the drug approval process, encouraging pharmaceutical companies to incorporate these tests into their clinical development strategies. The rise of precision medicine and the growing adoption of personalized treatment approaches are also propelling market growth. Furthermore, advancements in molecular diagnostics technologies, such as NGS and digital PCR, are enhancing the accuracy and efficiency of companion diagnostics, making them more accessible and reliable. The expansion of biomarker discovery and the increasing use of biomarkers in drug development are generating new opportunities for the market. Additionally, the collaboration between diagnostic companies and pharmaceutical firms is fostering innovation and accelerating the development of new companion diagnostics. These factors collectively contribute to the robust growth and widespread adoption of companion diagnostics, transforming the landscape of personalized medicine and improving patient care.
Report Scope
The report analyzes the Companion Diagnostics market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.Segments: Product & Service (Assay kits & Reagents, Software & Services); Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Other Technologies); Indication (Oncology, Neurology, Other Indications); End-Use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Other End-Uses).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Assay kits & Reagents segment, which is expected to reach US$9.7 Billion by 2030 with a CAGR of a -0.4%. The Software & Services segment is also set to grow at 1.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $4.2 Billion in 2024, and China, forecasted to grow at an impressive -0.3% CAGR to reach $2.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Companion Diagnostics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Companion Diagnostics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Companion Diagnostics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Molecular, Agilent Technologies, Inc., bioMérieux SA, Cepheid, Danaher Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 47 companies featured in this Companion Diagnostics market report include:
- Abbott Molecular
- Agilent Technologies, Inc.
- bioMérieux SA
- Cepheid
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Foundation Medicine Inc.
- Laboratory Corporation of America® Holdings
- Leica Biosystems Nussloch GmbH
- Merck & Co. Inc.
- Myriad Genetics Inc.
- NeoGenomics Laboratories, Inc.
- QIAGEN N.V.
- Quest Diagnostics Inc.
- Thermo Fischer Scientific Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Molecular
- Agilent Technologies, Inc.
- bioMérieux SA
- Cepheid
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Foundation Medicine Inc.
- Laboratory Corporation of America® Holdings
- Leica Biosystems Nussloch GmbH
- Merck & Co. Inc.
- Myriad Genetics Inc.
- NeoGenomics Laboratories, Inc.
- QIAGEN N.V.
- Quest Diagnostics Inc.
- Thermo Fischer Scientific Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 15.1 Billion |
Forecasted Market Value ( USD | $ 15.4 Billion |
Compound Annual Growth Rate | 0.3% |
Regions Covered | Global |